hCG Blood Test Explained: What It Measures and Why It's Ordered

Human chorionic gonadotropin (hCG) is a glycoprotein hormone produced principally by syncytiotrophoblast cells of the placenta, and it is one of the most frequently measured analytes in clinical laboratories. A blood (serum or plasma) hCG test reports the concentration of hCG and, depending on the assay design, some of its structural relatives. This page summarises what the published literature says the test measures, the contexts in which clinicians have been described as ordering it, and the analytical caveats researchers have documented. This page is for educational purposes only and is not medical advice; consult a licensed physician or the clinician who ordered the test about what any individual result means.

What the Analyte Is and Where It Comes From

hCG is a heterodimer consisting of an alpha subunit shared with luteinising hormone, follicle-stimulating hormone and thyroid-stimulating hormone, and a beta subunit that gives the molecule its hormone-specific identity. A review of hCG in pregnancy diagnostics described the hormone as a central product of trophoblast tissue whose measurement underpins modern pregnancy testing, and noted that circulating hCG exists in several molecular forms rather than as one uniform species (PMID 21635878). A separate review of hCG-related molecules catalogued the forms that reach blood and urine — intact hCG, hyperglycosylated hCG, free beta subunit, nicked variants and the urinary beta-core fragment — and reported that commercial immunoassays differ in which of these they recognise (PMID 27306471).

Although the placenta is the dominant source in pregnancy, the literature on elevated hCG outside of pregnancy described additional origins, including pituitary production and synthesis by certain tumours, which is why the same analyte appears in both obstetric and oncological settings (PMID 17868485).

What the Blood Test Actually Measures

Most contemporary serum hCG tests are automated immunoassays that use two antibodies to capture and detect the molecule. Because the antibody pair determines which epitopes are seen, a review of hCG-related molecules reported that assays vary in their recognition of intact hormone versus free beta subunit and hyperglycosylated forms, so values from different platforms are not always interchangeable (PMID 27306471). The pregnancy diagnostics review made a similar point about standardisation and the need to interpret serial values using the same method where possible (PMID 21635878).

Qualitative versus quantitative testing

Qualitative tests return a positive or negative result against a fixed cut-off; quantitative serum tests return a numeric concentration, usually in international units per litre. The pregnancy diagnostics literature described quantitative serum measurement as the form used when a trend over time, rather than a yes/no answer, is the clinical question (PMID 21635878).

Variant-specific assays

Specialised laboratories also run assays targeted at particular hCG forms. Work on laboratory detection of gestational trophoblastic disease described assays directed at hyperglycosylated hCG and free beta subunit, and reported that variant-aware testing improved detection in trophoblastic disease compared with intact-hormone measurement alone (PMID 15469850).

Why Clinicians Order an hCG Blood Test, as Described in the Literature

Confirming and following early pregnancy

The pregnancy diagnostics review described serum hCG as the analyte that allows pregnancy to be detected shortly after implantation and tracked thereafter (PMID 21635878). A widely cited commentary on serial measurement examined how clinicians use repeated values to characterise an early gestation and reported that the rate of change, rather than a single number, carries most of the information (PMID 23031160).

Evaluating suspected ectopic pregnancy

A clinical review of ectopic pregnancy described the combination of quantitative serum hCG with transvaginal ultrasonography as the central diagnostic approach, with hCG values interpreted alongside what imaging does or does not show (PMID 16217116). The same review discussed medical and surgical management options once the diagnosis is established (PMID 16217116). A multi-centre double-blind randomised trial compared methotrexate with placebo in early tubal ectopic pregnancy, and the trial report described serum hCG trends as the outcome measure used to judge resolution (PMID 22540910).

Gestational trophoblastic disease

Researchers reviewing laboratory detection of gestational trophoblastic disease reported that hCG and its variants serve both as diagnostic markers and as the basis for post-treatment surveillance, because trophoblastic tissue is the archetypal hCG-producing tissue (PMID 15469850). That review also emphasised that assay selection matters in this setting, since some methods under-detect the variant forms these tumours secrete (PMID 15469850).

Second-trimester screening panels

hCG also appears as one component of multi-analyte prenatal screening. A review of second-trimester serum markers described panels combining alpha-fetoprotein, hCG, unconjugated estriol and inhibin A to generate individualised risk estimates for chromosomal and structural conditions, and stressed that such panels are screening rather than diagnostic tools (PMID 16104669).

Oncology and tumour marker use

A review of hCG in cancer reported that hCG and particularly its free beta subunit are expressed by germ cell tumours and by a proportion of epithelial malignancies, and discussed their use as circulating markers (PMID 15234236). A more recent analysis of intracranial germinomas examined hCG-related tumour markers in serum and cerebrospinal fluid, and reported both diagnostic value and specific pitfalls when different hCG assays were applied to the same patients (PMID 36745216).

Placental pathology research

A 2020 review of biomarkers for abnormally invasive placenta surveyed maternal circulating markers that investigators have studied for antenatal prediction, and reported that no single biochemical marker had achieved standalone diagnostic performance in the published series examined (PMID 32174305).

What Published Studies Associate With High hCG Values

The literature links elevated hCG to several distinct situations, and the reviews consistently note that context determines meaning. A survey of elevated hCG outside of pregnancy set out a differential that included trophoblastic and germ cell tumours, non-trophoblastic malignancies, pituitary-derived hCG in the perimenopausal and postmenopausal setting, and analytical false positives (PMID 17868485). The cancer review reported that hCG beta subunit expression was detectable across a range of tumour types and had been studied in relation to prognosis (PMID 15234236).

Within obstetrics, the trophoblastic disease review described markedly raised hCG as a characteristic laboratory finding in molar and other trophoblastic lesions (PMID 15469850), while the second-trimester screening review reported that raised hCG within a multi-marker panel shifts calculated risk estimates rather than establishing any diagnosis on its own (PMID 16104669). None of these associations translates into an interpretation of an individual person's result.

What Published Studies Associate With Low or Slowly Rising Values

The commentary on serial hCG reported that patterns of slow rise, plateau or fall have been studied as indicators that a pregnancy may not be progressing normally, while cautioning that overlap between patterns limits certainty in any single case (PMID 23031160). The ectopic pregnancy review similarly described abnormal hCG trajectories as a trigger for further imaging and clinical assessment rather than as a diagnosis in themselves (PMID 16217116).

Because of these limits, investigators have looked at complementary analytes. A systematic review and meta-analysis of kisspeptin examined its diagnostic value for early pregnancy outcome and reported that kisspeptin measurement showed discriminative performance in the pooled studies analysed, positioning it as a research adjunct rather than a replacement for established testing (PMID 35212930).

Assay and Interpretation Caveats: What Studies Report

Several documented analytical problems affect hCG measurement, and the reviews treat awareness of them as part of competent interpretation.

• Heterophile antibody interference. The review of elevated hCG outside pregnancy reported that human anti-animal antibodies can produce persistently positive serum results with negative urine testing, a pattern described in the literature as phantom hCG (PMID 17868485).
• Variant recognition. Researchers reported that assays differ in detecting hyperglycosylated and nicked forms, so two platforms can return different concentrations on the same specimen (PMID 27306471).
• Under-detection in trophoblastic disease. The trophoblastic disease review reported that some assays missed variant-predominant hCG and recommended method awareness during surveillance (PMID 15469850).
• Marker-specific pitfalls in neuro-oncology. The germinoma analysis reported discrepancies between hCG and beta-hCG assay results and between serum and cerebrospinal fluid measurements (PMID 36745216).
• Standardisation. The pregnancy diagnostics review discussed calibration and standardisation issues that limit direct comparison of values across methods (PMID 21635878).

What a Single Value Cannot Establish

The clearest statement in this literature comes from the serial-measurement commentary, which reported that hCG alone cannot localise a pregnancy, cannot date it precisely and cannot independently establish viability (PMID 23031160). The ectopic pregnancy review reinforced that hCG findings are interpreted together with ultrasonography and clinical findings (PMID 16217116). Reference intervals printed on laboratory reports are method-specific, and the published reviews emphasise that comparing a number against a generic range ignores the assay, the clinical context and the trend over time (PMID 27306471).

Summary of the Evidence Landscape

Across these publications, hCG emerges as a well-characterised but unusually complex analyte: a family of molecules produced by trophoblast and, in defined circumstances, by pituitary and tumour tissue, measured by immunoassays with differing variant specificity, and used in obstetric, screening and oncological pathways (PMID 21635878, PMID 17868485, PMID 15234236). Researchers repeatedly framed the result as one input among several, with the ordering clinician integrating it with imaging, history and examination (PMID 23031160).

References

• Human chorionic gonadotropin in pregnancy diagnostics (Clinica Chimica Acta, 2011)
• hCG - related molecules and their measurement (Ginekologia Polska, 2016)
• What serial hCG can tell you, and cannot tell you, about an early pregnancy (Fertility and Sterility, 2012)
• Diagnosis and treatment of ectopic pregnancy (CMAJ, 2005)
• Methotrexate vs placebo in early tubal ectopic pregnancy: a multi-centre double-blind randomised trial (Reviews on Recent Clinical Trials, 2012)
• Advances in the clinical laboratory detection of gestational trophoblastic disease (Clinica Chimica Acta, 2004)
• Elevated HCG outside of pregnancy — diagnostic considerations and laboratory evaluation (Obstetrical & Gynecological Survey, 2007)
• Human chorionic gonadotropin in cancer (Clinical Biochemistry, 2004)
• Clinical significance and pitfalls of human chorionic gonadotropin-related tumor markers for intracranial germinomas (Child's Nervous System, 2023)
• Second trimester serum markers (Seminars in Perinatology, 2005)
• Biomarkers of abnormally invasive placenta (Placenta, 2020)
• Diagnostic Value of Kisspeptin Levels on Early Pregnancy Outcome: a Systematic Review and Meta-analysis (Reproductive Sciences, 2022)